Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma

Autor: G. J. Swansbury, Paul Mitchell, Kuan A, Stanley W. Ashley, R. L. Powles, Samar Kulkarni, T. J. Powles, Jennifer Treleaven, Radovan Saso, Jayesh Mehta
Rok vydání: 2000
Předmět:
Oncology
Cancer Research
medicine.medical_treatment
Translocation
Genetic

hemic and lymphatic diseases
Antineoplastic Combined Chemotherapy Protocols
Life Tables
Prospective Studies
Registries
Aged
80 and over

Leukemia
Radiation-Induced

education.field_of_study
Incidence
Secondary Myelodysplastic Syndrome
Regular Article
Neoplasms
Second Primary

Middle Aged
Combined Modality Therapy
England
Leukemia
Myeloid

Acute Disease
Female
medicine.drug
Risk
medicine.medical_specialty
Mitomycin
Population
Breast Neoplasms
mitoxantrone
breast cancer
Breast cancer
Internal medicine
medicine
Humans
acute myeloid leukaemia
Genetic Predisposition to Disease
education
Survival analysis
Aged
Mitoxantrone
Chemotherapy
business.industry
Myelodysplastic syndromes
medicine.disease
Survival Analysis
myelodysplastic syndrome
Surgery
Tamoxifen
Methotrexate
Myelodysplastic Syndromes
business
Follow-Up Studies
Zdroj: British Journal of Cancer
ISSN: 1532-1827
0007-0920
DOI: 10.1054/bjoc.2000.1196
Popis: Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years. Median duration of survival from diagnosis of MDS/AML was 10 months and six patients died. The crude incidence of developing MDS/AML after MMM or MM chemotherapy was 15 per 100 000 patient years follow-up, while the actuarial risk was 1.1% and 1.6% at 5 and 10 years respectively. MTZ-based regimens carry a 10 × higher risk of subsequent MDS/AML compared to that seen in the general population. © 2000 Cancer Research Campaign
Databáze: OpenAIRE